Vifor : FDA Approves Korsuva Injection To Treat Moderate-to-severe Pruritus In Hemodialysis Patients

The U.S. Food and Drug Administration has approved Korsuva or difelikefalin for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, Vifor Pharma and Cara Therapeutics (CARA) said in a statement on Tuesday.

Vifor Pharma expects to begin to market Korsuva injection in the first-quarter of 2022 with reimbursement expected in the first-half of 2022.

Korsuva injection is a first-in-class kappa opioid receptor agonist that targets the body's peripheral nervous system.

The companies have agreed to an exclusive license to commercialize Korsuva injection in the United States. The agreement features a Cara 60%, Vifor Pharma 40% profit-sharing arrangement in non-Fresenius Medical Care clinics in the U.S.

As per a previous deal, Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have agreed to market KORSUVA injection to Fresenius Medical Care North America dialysis clinics in the U.S. under a Cara 50%, Vifor Pharma 50% profit-sharing arrangement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
German sportswear company Adidas AG said Wednesday it will withdraw its request to block the application by the Black Lives Matter movement to trademark a yellow three-stripe design similar to Adidas' branding. This move by Adidas comes just 48 hours after it had filed an objection to the U.S. Patent and Trademark Office against the use of the three parallel stripes design. Generative artificial intelligence or AI technologies, including the highly popular ChatGPT, could expose around 300 million full-time jobs around the world to automation, a report by Goldman Sachs predicts, deepening the rising fears about job security. According to a new research report by GS economists, "The Potentially Large Effects of Artificial Intelligence on Economic Growth",.. UBS Group AG has called back its former Chief Executive Officer Sergio Ermotti to lead the Swiss banking giant amid the new challenges and priorities it faces following its planned acquisition of troubled domestic rival Credit Suisse Group AG. Following the news, UBS shares were gaining more than 2 percent in Swiss trading as well as in pre-market activity on the NYSE.
Follow RTT